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Background: The receptor for urokinase-type plasminogen activator (uPAR) is associated with cancer development
and progression. Within the tumor microenvironment uPAR is expressed by malignant cells as well as tumor-associated
stromal cells. However, the contribution of uPAR expression in these stromal cells to malignancy and patient
survival in colorectal cancer is still unclear. This study compares the association of uPAR expression in both
colorectal tumor-associated stromal cells and neoplastic cells with clinico-pathological characteristics and patient
survival using tissue micro arrays (TMA).
Methods: Immunohistochemical staining of uPAR expression was performed on tumor tissue from 262 colorectal
cancer patients. Kaplan-Meier, log rank, and uni- and multivariate Cox’s regression analyses were used to calculate
associations between uPAR expression and patient survival.
Results: In the colorectal tumor-associated stromal microenvironment, uPAR is expressed in macrophages,
(neoangiogenic) endothelial cells and myofibroblasts. uPAR expression in tumor-associated stromal cells and
neoplastic cells (and both combined) were negatively associated with overall survival (OS) and Disease Free
Survival (DFS). Uni- and multivariate Cox’s regression analysis for combined uPAR expression in tumor-associated
stromal and neoplastic cells showed significant and independent negative associations with OS and DFS. Only
uPAR expression in tumor-associated stromal cells showed independent significance in the uni- and multivariate
analysis for DFS.
Conclusion: This study demonstrates a significant independent negative association between colorectal cancer
patient survival and uPAR expression in especially tumor-associated stromal cells.
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In various cancer types, enhanced expression of uPAR is
associated with worse patient prognosis and survival.
This study evaluates in colorectal cancer whether the as-
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reproduction in any medium, provided the orby malignant cells as well as high uPAR expression by
tumor-associated stromal cells were independently cor-
related with worse patient survival.Introduction
Although the incidence of colorectal cancer is varying
worldwide, in the western world it is the third most fre-
quent cancer type [1]. To date, primarily the anatomic ex-
tent of the tumor is used to predict patient prognosis and
select optimal treatment strategies. However these classifi-
cation systems are rather unspecific. Novel techniques,
able to define unique molecular tumor characteristics,al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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tient care. As a consequence, biomarkers that are able to
classify tumors and are coherent with patient survival are
desperately needed [2]. The urokinase-type plasminogen
activator receptor (uPAR) might have the potential to be
such a marker [3].
A pivotal characteristic of malignant tumors is the in-
creased ability to degrade extracellular matrix (ECM),
enabling malignant invasion and metastasis. The urokinase-
type plasminogen activation (uPA) system plays a key role
in tissue remodeling and ECM degrading [4]. uPAR, the
membrane-bound receptor for uPA, has originally been
identified in a monocyte/macrophage human cell line
and is recognized in many physiological and pathologic
conditions in which tissue remodeling is involved [5].
Binding of uPA to uPAR is a pre-requisite for the local
activation of uPA, initiating plasmin-mediated extracel-
lular matrix degrading [6]. Therefore, uPAR expression
is closely related with pericellular proteolysis and in that
manner facilitates (cancer) cell migration and invasion.
Besides its receptor function, uPAR also mediates cell sig-
naling, chemotaxis, proliferation, and tumor survival [7].
Over-expression of the urokinase receptor has been
determined in the majority of malignant tumors, includ-
ing pre-malignant colorectal adenocarcinomas, colorec-
tal cancers and colorectal metastases [3,8,9]. Expression
of uPAR is observed in both neoplastic as well as tumor-
associated stromal cells of various tumor types including
colorectal [10-12]. However, the correlation of uPAR ex-
pression in these stromal cells with malignancy and
patient survival in colorectal cancer is still unclear. This
study investigated the relationship of uPAR expression
in tumor-associated stromal cell with clinical and follow-
up data in a large panel of tumor tissues from colorectal
cancer patients.
Methods
Patient and tumor characteristics
Tumor tissue samples were obtained from 262 patients
in the period from 1991 to 2001 at time of primary sur-
gery at the Leiden University Medical Center and were
evaluated for histo-pathological characteristics by quali-
fied pathologists according to current standards. Patient
and tumor characteristics were collected retrospectively
and are partly depicted in Table 1. Patients with pre-
operative therapy or a history of cancer other than basal
cell carcinoma (n = 9) or cervical carcinoma in situ (n = 1),
and tumors which could not be evaluated for uPAR ex-
pression in both tumor-associated stromal cells and neo-
plastic cells were excluded, resulting in 262 usable tumors.
Median age at operation was 66 years (range 30–91) and
136 (52%) patients were men. All patients had a proven
primary adenocarcinoma of which 98 (37%) were located
in the right colon, 99 (38%) in the left, and 65 (25%) in therectum. Median follow-up was 7.7 years (range 0–20)
calculated from the date of surgery. Tumor staging was
determined using the tumor node metastasis (TNM) clas-
sification. Tumor differentiation grades were available for
207 patients; 49 (24%) tumors were well differentiated and
158 (76%) were moderate or poorly differentiated. Distant
metastasis developed in 44 (17%) patients. At the end of
the follow-up period 96 of the patients (37%) were still
alive. All samples were handled in an anonymous fashion
according to the national ethical guidelines (‘Code for
Proper Secondary Use of Human Tissue,’ Dutch Feder-
ation of Medical Scientific Societies) and approved by the
Institutional Ethics Committee of the Leiden University
Medical Center.
Tissue micro array (TMA) production
Formalin-fixed paraffin-embedded tissue blocks of the
primary tumors were collected from the pathology depart-
ment. Sections were cut for haematoxylin-eosin staining
and histopathologically representative tumor regions were
used for preparation of TMA blocks. From each donor
block, three 0.6 mm diameter tissue cores were punched
from tumor areas and transferred into a recipient paraffin
block using a custom-made precision instrument. Because
the TMA was designed to evaluate protein expression
throughout the whole tumor, cores where taken from
three different locations across the tumor tissue, avoiding
necrotic or invasive areas.
Immunohistochemistry
Immunohistochemical (IHC) staining on the TMA was
performed on 4 μm sections cut from each TMA receiver
block. TMA sections were deparaffinized and rehydrated.
Endogenous peroxidase was blocked for 20 minutes in
0.3% hydrogen peroxide in methanol. The slides were
treated for antigen retrieval in citrate buffer for 10 minutes
at 95°C (DAKO PT Link). Sections were incubated over-
night with the uPAR specific antibodies at pre-determined
optimal dilution. After 30 minutes of incubation with
DAKO envision +HRP anti-mouse (K4001; DAKO Cyto-
mation, Glostrup, Denmark) the sections were visualized
using diaminobenzidine solution (DAB+; DAKO kit).
Sections were counterstained with haematoxylin, dehy-
drated and finally mounted in malinol (Waldeck-division
Chroma). To compensate for possible loss of antigen de-
tectability due to the long inclusion period of the patients,
the primary uPAR antibodies were incubated overnight
[13]. The uPAR staining was not correlated with operation
date (not shown).
IHC on the whole tumor slides was performed on 7 con-
secutive slides from the same tumor sample. Tissue sec-
tions from whole tumors were obtained and (pre) treated
in the same manner as the TMA slides (described above)
except for the section thickness (6 μm) and the mounting
Table 1 Uni- and multivariate analyses for Overall Survival (OS) and Disease Free Survival (DFS) on patient/tumor characteristics and uPAR expression in
tumor-associated stromal cells and neoplastic cells (and both combined) from 262 colorectal tumor patients are displayed
Overall Survival (OS) Disease Free Survival (DFS)
Univariate (OS) Multivariate (OS) Univariate (DFS) Multivariate (DFS)
Parameter n HR 95% CI p-value HR 95% CI p-value HR 95% CI p-value HR 95% CI p-value
Clinical data (total) 262
Age in years <65 109 1.000 0.000 1.000 0.000 1.000 0.000 1.000 0.000
≥65 153 3.381 2.360-4.842 3.648 2.537-5.245 3.058 2.172-4.307 3.309 2.338-4.682
TNM Stage I 47 1.000 0.000 1.000 0.000 1.000 0.000 1.000 0.000
Stage II 97 1.522 0.910-2.547 1.699 1.013-2.850 1.513 0.927-2.469 1.686 1.030-2.760
Stage III/IV 118 3.590 2.208-5.838 4.034 2.473-6.580 3.199 2.006-5.102 3.560 2.223-5.700
DifferentiationI Grade 1 49 1.000 0.451 1.000 0.663
Grade 2+ 158 1.174 0.773-1.783 1.093 0.733-1.630
MSIII MSS 184 1.000 0.457 1.000 0.429
MSI 26 0.816 0.477-1.396 0.815 0.491-1.353
SizeIII in mm <50 179 1.000 0.589 1.000 0.396
≥50 82 1.093 0.791-1.511 1.146 0.837-1.568
MucinousIV No 220 1.000 0.447 1.000 0.248
yes 36 0.850 0.558-1.293 0.790 0.529-1.179
uPAR in tumor cells Low 152 1.000 0.036 1.000 0.177 1.000 0.037 1.000 0.318
High 110 1.387 1.021-1.883 1.241 0.907-1.697 1.372 1.019-1.848 1.168 0.861-1.585
uPAR in stromal cells Neg 38 1.000 0.033 1.000 0.067 1.000 0.014 1.000 0.031
Pos 224 1.688 1.044-2.729 1.580 0.968-2.578 1.819 1.127-2.936 1.713 1.049-2.796
Combined uPAR expressionV Neg 38 1.000 0.032 1.000 0.037 1.000 0.019 1.000 0.032
Pos/Low 119 1.508 0.909-2.501 1.503 0.905-2.495 1.646 0.995-2.724 1.661 1.002-2.754
Pos/High 105 1.925 1.159-3.198 1.906 1.146-3.170 2.036 1.230-3.370 1.959 1.182-3.247
P-values of 0.05 or less are considered significant and are presented in bold. Both uPAR expressions in neoplastic and tumor-associated stromal cells were significantly related to OS in the univariate analysis. Both
neoplastic and tumor-associated stromal cell uPAR expression showed significance in the univariate analysis for DFS. Combined uPAR expression reached significance for OS and DFS in a multivariate Cox’s regression
analysis including the factors age and TNM which were significant in the univariate analysis.
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consecutive tumor sections were simultaneously stained
for the stromal markers. Antibodies against the following
antigens in the corresponding concentrations were used:
Vimentin for mesenchymal cells in 0.4 μg/ml (Santa Cruz;
clone V9, Santa Cruz, USA), CD68 as marker for mono-
cytes/macrophages in 2.5 μg/ml (DAKO; clone KP1),
CD31 for endothelial cells in 1.7 μg/ml (DAKO; clone
JC70A), CD105 for activated endothelial cells in 5 μg/ml
(neo-angiogenic) (R&D systems, Abington, UK), α-SMA
for myofibroblasts in 0.07 μg/ml (Progen; clone ASM-1,
Heidelberg, Germany), cytokeratin for epithelial cells
0.4 μg/ml (DAKO; AE1/AE3) and uPAR/CD87 expres-
sion in 2.4 μg/ml (ATN-615) gift from prof. Mazar [14].
Scoring methods
The 0.6 mm cores of all 262 colorectal cancer patients
were semi-quantitatively scored for the proportion of
uPAR positive neoplastic and tumor-associated stromal
cells by two independent examiners (MB, FV). Cores were
used when 50% or more was occupied by tissue. Patients
with less than two evaluable cores were excluded which
resulted in 182 (69.5%) patients with 3 evaluable cores
and 80 (30.5%) patients with 2 usable cores. The percent-
age of positive tumor cells and stromal cells within each
core were scored independently and categorized in 0–5,
5–25, 25–50, 50–75 and 75-100%. The median of the trip-
licate or duplicate cores were used for data analysis. In a
preliminary log-rank/Kaplan-Meier analysis the discrim-
inative values for uPAR scoring categories for Overall Sur-
vival (OS) and Disease Free Survival (DFS) were assessed
(data not shown). In the final analysis percentages of
uPAR staining were dichotomized as follows: absence
(<5%) or presence (≥5%) of uPAR in tumor-associated
stromal cells and low (<50%) or high (≥50%) expression
of uPAR in neoplastic cells. The Spearman rank analysis
and Kappa statistics were performed to calculate inter-
observer agreement. To finalize the scoring, in case of
discrepancies, both examiners reviewed the cores to-
gether to reach consensus.
Statistical analysis
Statistical analyses were conducted using SPSS statistical
software (version 20.0 for Windows, SPSS Inc, Chicago,
USA). The Pearson Chi-Square test was performed to
compare nominal variables. The Kaplan–Meier method
was used for survival plotting and log-rank test for com-
parison of the survival curves. Time to events in OS and
DFS analysis was defined as follows: from time of primary
surgery to time of death or cancer relapse. Multivariate
Cox’s proportional hazard analyses were performed with
the factors that were significant in the univariate analysis,
including age and TNM. Hazard ratios (HR) and their 95%
confidence intervals (95% CI) are included. All statisticaltests are conducted two-sided and p-values of 0.05 or less
are considered significant.
Results
Patient and tumor characteristics
Immunopositivity for uPAR in tumor-associated stromal
cells was found in 224 (85%) tumors, whereas low uPAR
expression in neoplastic cells was shown in 152 (58%)
tumors. From all the clinico-pathological parameters, in-
cluding the administration of adjuvant therapy and the
grade, location, and size of the tumor, only high uPAR
expression on tumor cells was significantly correlated,
where high uPAR expression was found in well differenti-
ated tumors. Further, no significant associations between
uPAR expression and the clinico-pathological parameters
were observed (data not shown). Inter- and intratumoral
uPAR specific staining was variable and associated with
both the cell membrane and cytoplasm in tumor and
tumor-associated stromal cells (Figure 1a). The degree of
expression was graded as low (58%) or high (42%) for
uPAR immunoreactivity in neoplastic cells and negative
(15%) or positive (85%) for expression in tumor-associated
stromal cells. No correlation was found between uPAR
expression on neoplastic cells and tumor-associated stro-
mal cells (p = 0.063). A moderate agreement between ob-
servers was seen. For tumor cells, Spearman rank analysis
gave 0.469 (p < 0.000) whereas Kappa statistics showed
0.47 (95% CI: 0.35-0.60). For stromal cells Spearman rank
analysis gave 0.450 (p < 0.000) whereas Kappa statistics
showed 0.42 (95% CI: 0.28-0.55).
Survival analysis
Kaplan Meier curves showed a significant negative associ-
ation between uPAR expression in neoplastic and tumor-
associated stromal cells with OS (p = 0.035 & p = 0.031)
and DFS (p = 0.036 & p = 0.013, Figure 2a). Both uPAR ex-
pression in neoplastic and tumor-associated stromal cells
were significant related to OS in the univariate analysis,
but both did not retain significance in the multivariate
analysis (p = 0.177 and p = 0.067, Table 1). For DFS, both
neoplastic and tumor-associated stromal cell uPAR expres-
sion showed significance in the univariate analysis (p =
0.037 and p = 0.014), but only uPAR expression in tumor-
associated stromal cells stayed significant in the multivari-
ate analysis (p = 0.031).
The combination of uPAR expression in both tumor-
associated stromal cells as well as neoplastic cells in three
subgroups showed a stepwise correlation in the log rank
analysis for both OS and DFS (p = 0.030 and p = 0.017)
(Figure 2b). Patients with negative uPAR expression in
tumor-associated stromal cells (−) showed better OS and
DFS, whereas patients with uPAR expression in tumor-
associated stromal cells as well as in neoplastic cells had
the worst (+/+), with the rest group (+/−) in between.
Figure 1 Immunohistochemical stainings of colorectal cancer tissue sections with anti-uPAR and anti-cell marker antibodies. a) uPAR
staining on TMA cores from tissue of colorectal cancer patients: I) Negative in neoplastic and stromal cells, II) positive in neoplastic and stromal
cells, III) positive in neoplastic and negative for stromal cells and IV) negative in neoplastic and positive for stromal cells. b) Sequential stained
sections showing expression of the urokinase receptor in comparison with various markers for tumor-associated stromal cells: I) with endothelial
cells, II) with monocytes/macrophages, III) neoangiogenic cells and IV) with myofibroblasts. Bars in a) and b) indicate ~50 μm.
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(p = 0.037) and DFS (p = 0.032) in the multivariate Cox’s
regression analysis as shown in Table 1.
uPAR expression in tumor-associated stromal cells
uPAR expression was present in various types of tumor-
associated stromal cells in sequential sections from whole
tumors. Figure 1b displays urokinase receptor staining in
(neoangiogenic) endothelial cells, tumor-associated mac-
rophages, and cancer-associated myofibroblasts. Not all
monocytes/macrophages found on the slides expressed
uPAR, but when present, it showed a more intense stain-
ing in comparison with uPAR positive neoplastic cells.
uPAR expression was frequently observed in endothelial
cells expressing both CD31 and CD105, underscoring
the presence of the urokinase receptor in intra-tumoral
neoangiogenic cells. uPAR was regularly but not consist-
ently found in tumor-associated myofibroblasts. uPAR
expression was especially associated with myofibroblasts
located in the invasive front of the tumor.
Discussion
This study demonstrates the relationship between en-
hanced expression of the urokinase receptor in colorectal
tumor-associated stromal cells and a significant worse
patient survival. Neoplastic cell and tumor-associated
stromal cell expression of uPAR in colorectal cancers
appeared to be independent from each other and pa-
tients with enhanced uPAR in both cell types showed
the worst prognosis.These data could partly explain the relatively strong cor-
relation between uPAR and survival as found in especially
breast cancer homogenate studies using ELISAs, versus
the generally less strong associations noticed in immuno-
histochemical studies scoring specific tumor cell uPAR
staining [3,15]. Immunohistochemical studies in general
score uPAR in malignant cells, neglecting the stromal
cells, whereas in ELISA-based studies the overall presence
of uPAR is measured. Although the correlation between
uPAR expression in neoplastic and tumor-associated stro-
mal cells and patient prognosis has been studied before in
breast cancer, the results are not consistent. Some studies
showed no significant relation with prognosis [16,17],
whereas others found a significant association with disease
free survival or relapse-free survival but not with overall
survival [18]. These variable results could partly be ex-
plained by the different IHC antibodies that were used.
uPAR is present in diverse configurations which are not
all detected equally well by the various anti-uPAR anti-
bodies. To circumvent this, we used an antibody, ATN-
615, which binds with high affinity (kd ~1 nM) to domain
D3 of uPAR and is extensively validated [17]. Therefore,
virtually all forms, i.e. full size or D2D3 fragments of cell-
bound uPAR are detected regardless whether the ligand
(uPA) is bound or not [19].
Our results obtained with TMA sections indicate that
neoplastic cell positivity correlates with patient survival,
like has been observed before using immunohistochem-
istry on whole tumor sections [20]. The use of TMA








Figure 2 Kaplan-Meier Overall Survival (OS) and Disease Free Survival (DFS) curves for uPAR expression in tumor tissues from 262
patients with colorectal cancer. a) Neoplastic cells (low <50% & high ≥50%) and tumor-associated stromal cells (neg <5%, pos ≥5%).
b) Combined uPAR expression, 3 groups: stromal cells negative for uPAR(−/), stromal cells positive for uPAR and low uPAR expression in
neoplastic cells (+/−), stromal cells positive for uPAR and high expression of uPAR in neoplastic cells (+/+).
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overcome the drawback of heterogeneity within the tumor,
it is argued that increasing the number of cores per tumor
will be sufficient [21]. Examining punches from different
representative locations within the tumor may reveal an
overview of the expression of an antigen similar to what is
obtained from whole sections. So far, no consensus exists
about the number and the location of the cores, which
could also depend on the nature of the marker of interest.
Our TMA consisted of 3 punches from different represen-
tative locations within the tumor.
Several scoring methods are used for the evaluation of
immunohistochemical stainings. We used only the pro-
portion of neoplastic and tumor stromal cells which ex-
press uPAR rather than the combination with the intensity
of the stainings like for instance the score proposed by
Remmele [22].
A recent study in gastric tumors indicates that especially
uPAR expression in gastric cancer cells in the peripheral
invasion zone is an independent prognostic factor foroverall survival [23]. Our observations in colorectal cancer
support these findings. In the colorectal tumor-associated
stromal microenvironment, uPAR expression was further-
more observed in monocytes/macrophages, (neoangio-
genic) endothelial cells and myofibroblasts, which is in line
with previously published studies [8,16,24]. Macrophages
and myofibroblasts are able to induce neoplastic tumor cell
proliferation, progression and metastasis via the secretion
of growth factors and cytokines [25-27]. Myofibroblasts
located in the tumor microenvironment modulate inflam-
matory responses by secreting pro-inflammatory cytokines,
resulting in recruitment of immune cells such as macro-
phages. Tumor-associated macrophages induce several
tumor promoting processes such as angiogenesis, extracel-
lular matrix breakdown, tumor cell migration, invasion,
and metastasis [28]. The pro-angiogenic growth factors se-
creted by both the tumor-associated myofibroblasts and
macrophages contribute to the ‘angiogenic switch’. This
switch results in vasculogenesis and the recruitment of
existing endothelial cells to proliferate, migrate, and form
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secure a steady supply of oxygen and nutrients and to
metastasize [29]. Overexpression of uPAR, focusing the
local proteolytic activity which is essential for matrix re-
modeling, seems to be a common feature, not only for
invasive cells, but also for cells that play key roles in
tumor cell support. The association between uPAR ex-
pression in the cancer-associated-stromal-cells and the
survival of the patients is probably a direct consequence
of the supportive effects of these cells on tumor prolifera-
tion. Our finding that stromal cells contribute sub-
stantially to the overall uPAR content within colorectal
cancers could also have an impact on the prognostic rele-
vance of soluble uPAR (suPAR) as has been reported by a
number of studies for various cancer types [30-35]. In
general, enhanced levels of s-uPAR and s-uPAR fragments
in blood and urine are found to be related with poor prog-
nosis. But the pattern of secreted suPAR-fragments was
highly diverse in a small number of ovarian carcinoma pa-
tients, which could have been caused by the of cell popu-
lation within the individual tumors [36].
The multi-faceted appearance of uPAR might also impli-
cate a potential role as tumor target. The possibility to
target multiple relevant cell types within the same tumor
might compensate for the relatively low overexpression on
malignant cancer cells compared with other tumor
markers, like EGFR, Her2/Neu or EpCAM. Using the
same anti-uPAR antibody as used in this study, tumor re-
gression was achieved in vivo in mice xenografted with
ovarian, colon and prostate cancer [37-39].
Conclusions
uPAR plays a major role in adhesion, migration, invasion
and metastasis of cancer. It is found in the majority of
colorectal tumors in malignant cells and in various types
of tumor-supportive tumor-associated stromal cells. Al-
though this study does not especially discriminate be-
tween the different stromal cells, our results show a
significant independent association between colorectal
cancer patient survival and uPAR expression in the gen-
eral tumor-associated stromal cells.
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